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Expression of phosphodiesterase 6 (PDE6) in
human breast cancer cells
Hongli Dong1, Kevin P Claffey1, Stefan Brocke2 and Paul M Epstein1*
Abstract
Considerable epidemiological evidence demonstrates a positive association between artificial light at night (LAN)
levels and incidence rates of breast cancer, suggesting that exposure to LAN is a risk factor for breast cancer.
There is a 30-50% higher risk of breast cancer in the highest LAN exposed countries compared to the lowest LAN
countries, and studies showing higher incidence of breast cancer among shift workers exposed to more LAN
have led the International Agency for Research on Cancer to classify shift work as a probable human carcinogen.
Nevertheless, the means by which light can affect breast cancer is still unknown. In this study we examined
established human breast cancer cell lines and patients’ primary breast cancer tissues for expression of genetic
components of phosphodiesterase 6 (PDE6), a cGMP-specific PDE involved in transduction of the light signal, and
previously thought to be selectively expressed in photoreceptors. By microarray analysis we find highly significant
expression of mRNA for the PDE6B, PDE6C, and PDE6D genes in both the cell lines and patients’ tissues, minimal
expression of PDE6A and PDE6G and no expression of PDE6H. Using antibody specific for PDE6β, we find expression
of PDE6B protein in a wide range of patients’ tissues by immunohistochemistry, and in MCF-7 breast cancer cells by
immunofluorescence and Western blot analysis. Considerable expression of key circadian genes, PERIOD 2, CLOCK,
TIMELESS, CRYPTOCHROME 1, and CRYPTOCHROME 2 was also seen in all breast cancer cell lines and all patients’
breast cancer tissues. These studies indicate that genes for PDE6 and control of circadian rhythm are expressed in
human breast cancer cells and tissues and may play a role in transducing the effects of light on breast cancer.
Keywords: Breast cancer; Cyclic nucleotide phosphodiesterase; PDE6; Light; Circadian clock genes; cGMP signaling
Introduction
Cyclic Nucleotide Phosphodiesterases (PDEs) are enco-
ded by 21 different genes grouped into 11 gene families
based on sequence similarity, mode of regulation, and
specificity for cAMP or cGMP as substrate (Francis,
et al. 2011; Lerner and Epstein 2006). There is conside-
rable interest in PDEs owing to studies showing them to
be excellent candidate targets for treating a wide range
of illnesses including hematological malignancies, os-
teoporosis and inflammatory and autoimmune diseases
(Epstein 2012; Francis, et al. 2011; Lerner and Epstein
2006; Vang, et al. 2010). Catalytic subunits of PDE6, a
cGMP-specific PDE, were thought to be photoreceptor-
specific, localized exclusively to the outer segment of
rods and cones in the eye, where they are crucial for the
transduction of light (Stryer 1986; Zhang and Cote 2005).
The rod outer segment (ROS) is a dual membrane system
composed of about 2000 disks surrounded by a physically
separate plasma membrane. The disks contain rhodopsin,
PDE6 and transducin. The plasma membrane contains a
cGMP-gated sodium channel. In the dark, the ROS con-
tains an unusally high concentration of cGMP (≈ 70 μM),
which activates the sodium channel and depolarizes the
membrane. When light impinges on rhodopsin on the
disks, it photoisomerizes its chromophore, which in turn
activates the GTP-binding protein, transducin, which acti-
vates the catalytic activity of PDE6 by dissociating its in-
hibitory γ subunits. PDE6 then very rapidly reduces the
cGMP concentration leading to inactivation of the sodium
channels and hyperpolarization of the plasma membrane
which is conveyed to the synapse at the other end of the
rod and communicated to other cells of the retina (Stryer
1986; Zhang and Cote 2005). In the human rod, PDE6 is
composed of two large (≈99 kDa) catalytic subunits, α and
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β, encoded by the PDE6A and PDE6B genes respectively,
two small (≈ 11 kDa) inhibitory γ subunits encoded by
PDE6G, and a small (≈ 17 kDa) δ regulatory subunit en-
coded by PDE6D. The human cone PDE6 contains two α’
catalytic subunits encoded by PDE6C, two inhibitory γ
subunits encoded by PDE6H, and a regulatory δ subunit
encoded by PDE6D (Ionita and Pittler 2007). The PDE6D-
encoded δ subunit (PDE6δ) is not specific to PDE6 in that
it binds to other enzymes and is expressed in other tissues
(Zhang, et al. 2004). Its function as part of the PDE6 en-
zyme is unclear, although it is generally found to be bound
to the soluble fraction of PDE6 in retina extracts and may
play a role in transport of PDE6 to the disks or its trans-
location to the plasma membrane (Cook, et al. 2001;
Zhang, et al. 2007). PDE6δ has also been shown to func-
tion as a cytosolic farnesyl-binding chaperone protein
for ras, which facilitates ras trafficking and signaling
(Chandra, et al. 2012). The γ inhibitory subunit of PDE6 is
also expressed in other tissues such as lung and kidney
cells (Guo and Ruoho 2008; Tate, et al. 2002) and has been
suggested to play a role in the activation of MAP kinase
by epidermal growth factor signaling (Wan, et al. 2003).
PDE6 catalytic activity has also been reported in chick
pineal gland where it is believed to mediate the light in-
duced inhibition of melatonin synthesis (Holthues and
Vollrath 2004; Morin, et al. 2001). In contrast to humans,
in chick, both in rods and pineal glands, the catalytic ac-
tivity of PDE6 appears to be comprised of homodimers of
two PDE6B-encoded β subunits, with no evidence for the
expression of PDE6A-encoded α subunits present in these
chick tissues (Huang, et al. 2004; Morin, et al. 2001). Inas-
much as cGMP has been shown to regulate proliferation
and apoptosis of breast cancer cells (Saravani, et al. 2012;
Tinsley, et al. 2011), we examined breast cancer cells for
the expression of PDE6 genes. In this paper we show sig-
nificant expression of PDE6B, PDE6C, and PDE6D, in hu-
man breast cancer cell lines and patients’ breast cancer
tissues.
Materials and methods
Materials
Breast cancer/uninvolved paired tissue array (catalog no.
BRC481) was obtained from Pantomics (San Francisco,
CA, USA). Tissues were classified as tumor or uninvolved
based upon H&E staining and immunohistochemistry
using anti-cytokeratin antibody and staged according to
the standard TNM classification by a certified physician.
Human breast adenocarcinoma estrogen receptor-positive
MCF-7 and T-47D, and estrogen receptor-negative MDA-
MB-231 and MDA-MB-435 cell lines were obtained from
American Type Culture Collection (Manassas, VA, USA).
Breast cancer tumor tissues for microarray analysis were
obtained from the Neag Cancer Center of the University
of Connecticut Health Center (UCHC) in a deidentified
manner. All procedures involving human tissue were ap-
proved by the UCHC Institutional Review Board. PDE6β
specific antibody (catalog no. NB120-5663) was from
Novus Biologicals (Littleton, CO). Alexa Fluor 350 conju-
gated goat anti-rabbit IgG was from Invitrogen (Carlsbad,
CA). Horseradish peroxidase conjugated goat anti-Rabbit
IgG was from GE Healthcare (Piscataway, NJ).
Cell culture
Cell lines were maintained in DMEM medium sup-
plemented with 10% fetal bovine serum, 2 mM L-glu-
tamine, 100 U/ml penicillin and 100 μg/ ml streptomycin,
at 37°C in a humidified atmosphere of 95% air and
5% CO2.
Microarray
Microarray analyses were performed with Illumina Ref8
bead chips according to the manufacturer’s directions.
Data analysis was performed with Illumina Gene Studio
software. Gene array data for cell lines or tumor samples
were treated as separate groups and normalized using
rank-invariant normalization of raw data. Statistical sig-
nificance of each value was determined based upon sig-
nal variance for multiple probes for each gene to assume
appropriate mRNA expression.
Western immunoblot analysis
Western immunoblotting analysis was performed as
described previously (Vang, et al. 2013). MB-231 and
MCF-7 breast cancer cells were centrifuged at 300 × g
for 5 min, washed twice with ice-cold phosphate buf-
fered saline (PBS), and lysed in RIPA buffer (50 mM Tri-
HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40,
0.25% Na-deoxycholate with 1:100 dilution Sigma pro-
tease inhibitor cocktail). Protein concentration was de-
termined using a Micro BCA Protein Assay Kit (Pierce,
Rockford, IL). Equal amounts of protein were loaded and
run on 10% SDS-PAGE gels. Proteins were then trans-
ferred onto Immobilon-p Transfer Membrane (Millipore).
Membranes were blocked with 5% BSA in Tris-buffered
saline (TBS) for 1 h at room temperature and probed with
1:200 dilution of PDE6β specific primary antibody (Novus
Biologicals) overnight at 4°C, washed three times with
TBS-T (TBS with 0.1% Tween 20) buffer, and incubated
with horseradish peroxidase-conjugated secondary anti-
body (GE Healthcare) at 1:5000 dilution for 1 h at room
temperature and then washed three more times. Proteins
were visualized with SuperSignal West Femto Maximum
Sensitivity Substrate (Pierce, Rockford, IL) using a Syn-
gene G:Box with Genesnap BioImaging software. Staining
with anti-GAPDH (glyceraldehyde-3-phosphate dehydro-
genase) antibody (Abcam) was used for loading control
and normalization.
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Immunofluorescence
MCF-7 and MDA-MB-231 cells were seeded on a slide
cell chamber at 5×103 cells/well. After growth for 24 h
the cells were washed 3 times with PBS, fixed in 4%
paraformaldehyde in PBS for 10 min and washed with
PBS 3 times. The fixed cells were blocked with 5% BSA
in PBS containing 0.2% Tween-20 at room temperature
for 2 h, incubated with primary anti-PDE6β antibody
(1:50) overnight at 4°C, washed 3 times and incubated
with Alexa Fluor conjugated secondary antibody (1:200)
for 1 h, washed 3 times in PBS, counterstained with 4',6-
diamidino-2-phenylindole (DAPI) (1:5000 in PBS) for
2–5 min, washed 3 times and examined by fluorescent
microscopy.
Immunohistochemistry
Immunohistochemistry was performed on 4 μm thick
paraffin sections from 16 cases of invasive breast cancer
with corresponding uninvolved tissue obtained from
Pantomics using primary PDE6β antibody and detection
with Vector ImmPRESS anti-rabbit Ig (peroxidase) poly-
mer detection kit using DAB substrate according to the
manufactuer’s protocol (Vector Laboratories, Burlingame,
CA, USA). Controls without addition of primary antibody
were performed to assure signal specificity. Nuclei were
counterstained using methyl green.
Results
Expression of PDE6 mRNA in breast cancer cell lines
Expression of the mRNA for PDE6 genes was examined
in the human breast adenocarcinoma estrogen receptor-
negative cell lines, MB-231 and MB-435, and in the es-
trogen receptor-positive cell lines, T47D and MCF-7, by
microarray analysis. Figure 1A shows the expression of
mRNA for PDE6 catalytic subunit genes, PDE6A, 6B,
and 6C. PDE6B was highly and significantly expressed in
MCF-7 cells and to a much smaller extent in T47D cells,
but not in MB-231 and MB-453 cells. PDE6C was highly
and significantly expressed in all four of these breast
cancer cell lines. PDE6A was minimally expressed at a
significant level only in MB-231 cells, and not in any of
the other breast cancer cells. Figure 1B shows the ex-
pression of mRNA for PDE6 regulatory subunit genes,
PDE6D, 6G, and 6H. No significant expression of genes
for the rod inhibitory subunit, PDE6G, or the cone in-
hibitory subunit, PDE6H, was seen in any of the cell
lines examined. The regulatory subunit gene, PDE6D,
was, however, highly expressed in all four breast cancer
cell lines.
Expression of PDE6 protein in breast cancer cell lines
Using antibody specific for PDE6β, the expression of
PDE6B protein was examined in MCF-7 and MB-231 cells
both by immunofluorescence and Western immunoblot
analysis. Consistent with PDE6B mRNA expression, as
shown in Figure 2, by immunofluorescence, high expres-
sion of PDE6B protein was also seen in MCF-7 cells and
the protein appeared to be expressed throughout the cell.
Little expression of PDE6B protein was seen in MB-231
cells by immunofluorescence, again consistent with the
mRNA expression. Also consistent with the PDE6B
mRNA expression, as shown in Figure 3, PDE6β specific
antibody recognized a band at ≈ 99 kDa in MCF-7 cells by
Western immunoblot analysis, but little expression of this
band was seen in MB-231 cells.
Microarray analysis of PDE6 mRNA in patients’ breast
cancer tissue
PDE6 gene expression was analyzed by microarray ana-
lysis in breast tumor tissue from eight breast cancer
patients. Similar to results with the breast cancer cell
lines (Figure 1), in patients’ tumor tissues, as shown
in Figure 4A, only very minimal expression of PDE6A
was seen, which only reached significance in two of
the eight patients, patient numbers 4 and 5. In con-
trast, PDE6B and PDE6C were significantly, and in many
cases highly, expressed in all eight patients’ tumor tissues.
Figure 1 Expression of PDE6 mRNA in breast cancer cell lines.
(A) Microarray analysis of PDE6 catalytic (PDE6A, 6B and 6C) subunit
mRNA expression. (B) Microarray analysis of PDE6 regulatory (PDE6D)
and inhibitory (PDE6G and 6H) subunit mRNA expression. **P < 0.01
and *P < 0.05.
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Examination of the expression of the PDE6 regulatory
genes, shown in Figure 4B, also closely paralleled that seen
in the breast cancer cell lines in that only very min-
imal expression for PDE6G was seen in any tissues,
and no significant expression was seen for PDE6H at
all, but considerable and significant expression was
seen for PDE6D in all eight patients’ breast tumor tis-
sues. Estrogen receptor expression was also examined
in these tissues to determine their estrogen receptor
status. As shown in Figure 4C, significant expression
of estrogen receptor α (ESR1) was seen in all patients’
samples except for patient number 2, although the degree
of expression varied considerably from patient to patient.
Based on these data, there does not appear to be any ob-
vious correlation between expression of PDE6 genes and
estrogen receptor status.
Expression of PDE6 protein in breast cancer tumors
Using antibody specific for PDE6β, the expression of
PDE6B protein was examined in sixteen cases of invasive
Figure 3 Expression of PDE6B protein in breast cancer cell lines
by Western immunoblot analysis. Protein extracted from MCF-7
and MDA-MB-231 cell lines were run on SDS-PAGE gels, transferred
to Immobilon-P membrane, probed with PDE6β specific antibody
and detected with horseradish peroxidase conjugated goat anti-Rabbit
IgG as described in Methods.
Figure 4 Expression of PDE6 and estrogen receptor mRNA in
patients’ breast cancer tissue. Breast cancer tumor tissues from eight
patients were analyzed by Illumina microarray analysis. (A) Microarray
analysis of PDE6 catalytic (PDE6A, 6B and 6C) subunit mRNA expression.
(B) Microarray analysis of PDE6 regulatory (PDE6D) and inhibitory
(PDE6G and 6H) subunit mRNA expression. (C) Microarray analysis of
estrogen receptor alpha mRNA expression. **P < 0.01 and *P < 0.05.
Figure 2 Expression of PDE6B protein in breast cancer cell lines
by immunofluorescence. MCF-7 and MDA-MB-231 cell lines were
stained with PDE6β primary and Alexa Fluor conjugated secondary
antibodies and counterstained with DAPI as described in Methods.
Controls were treated identically except that the primary antibody
was omitted.
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breast cancer and surrounding tissue by immunohisto-
chemistry. Considerable expression of PDE6B protein
was seen in all sixteen breast cancer tissue samples, re-
gardless of what type of breast carcinoma they repre-
sented. The sixteen samples contained eleven cases of
ductal carcinoma, three cases of lobular carcinoma, and
two cases of poorly differentiated carcinoma. PDE6B ex-
pression in a representative example of each of these
types of cancer is shown in Figure 5. Considerable PDE6B
expression is seen in all of these, and expression is seen in
the uninvolved tissue surrounding these tumors as well. In
controls where primary PDE6β antibody was omitted, no
labeling was seen at all (not shown). Although the tissue
samples surrounding the tumors are classified as unin-
volved, these do not necessarily represent normal breast
tissue, since they are in proximity with the tumor and thus
may already be in a precancerous state, exhibiting changes
such as non-cancerous atypia or hyperplasia.
Expression of phototransduction genes, wnt signaling
genes, and circadian clock genes in breast cancer cell
lines and patients’ tumors
Bazhin et al. showed that in addition to PDE6, other
proteins in the phototransduction pathway, including
rhodopsin, transducin, cyclic nucleotide gated (CNG)
channels, guanylyl cyclase, rhodopsin kinase, recoverin
and arrestin, are also expressed to varying degrees, al-
though all to a lesser extent than PDE6, in melanoma
cell lines and tissues, and they refer to these expressed
genes as cancer-retina antigens (Bazhin, et al. 2007). It
was also shown that PDE6 is expressed in murine F9
teratocarcinoma cells (Ahumada, et al. 2002) and that
Figure 5 Expression of PDE6B protein in patients’ breast cancer tissue. Immunohistochemistry with PDE6β antibody was performed on
paraffin sections from sixteen cases of invasive breast cancer, which included eleven cases of ductal, three cases of lobular, and two cases of
poorly differentiated carcinoma, with corresponding uninvolved tissue. All sixteen tissue samples were positive for PDE6B expression and a
representative sample of each of the three types of carcinoma with its corresponding uninvolved tissue is shown.
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PDE6 in these cells as well as in melanoma cells (Bazhin,
et al. 2010) is activated by the noncanonical Wnt signaling
pathway through Wnt5a binding to Frizzled-2 receptors,
leading to activation of transducin and subsequent activa-
tion of PDE6. The result of this is a reduced concentration
of cGMP and increased concentration of Ca2+. Additional
studies have shown that expression of key circadian clock
genes are under the control of cGMP (Golombek, et al.
2004; Oster, et al. 2003; Plano, et al. 2012), and that dis-
ruption of the normal expression of these genes can result
in the development of cancers, including breast cancer
(Fu, et al. 2011; Fu and Lee 2003; Gery and Koeffler 2010;
Hoffman et al. 2010a,b). For these reasons, we also exam-
ined the expression of other phototransduction pathway
genes, Wnt signaling genes, and circadian genes in breast
cancer cells and tissues. As shown in Table 1, examination
of phototransduction genes in breast cancer cells and tis-
sues reveals highly significant expression (p < 0.01) of vari-
ous isoforms of transducin, in addition to PDE6, but only
minimal and sporadic expression of any of the other genes
in the phototransduction pathway. Significant expression
ofWNT5A was observed in all of the patients’ breast can-
cer tissues and in the MB-435 and MB-231 cells, but not
in the MCF-7 and T47D cells. FRIZZLED-2 (FZD2) was
significantly expressed in all breast cancer cell lines and
tissues examined. The key circadian genes, PERIOD 2
(PER2 variant 2), CLOCK, TIMELESS, CRYPTOCHROME
1 (CRY1) and CRYPTOCHROME 2 (CRY2) were all also
significantly expressed in all breast cancer cell lines and all
patients’ breast cancer tissues examined.
Discussion
These studies demonstrate that PDE6, formerly thought
to be photoreceptor-specific, is expressed in breast can-
cer cells and tissues both at the mRNA and protein level.
In contrast, microarray analysis of PDE6 in completely
normal tissue, using a murine system, shows PDE6 ex-
pression to be restricted to photoreceptor tissue, with no
evidence at all of any PDE6 expression in normal breast
epithelium (Laule, et al. 2006). Several other studies have
also detected expression of PDE6 in non-photoreceptor
tissues; specifically, in murine F9 embryonic teratocar-
cinoma cells, in melanoma cells, and in human lung tis-
sue (Ahumada, et al. 2002; Bazhin, et al. 2010; Nikolova,
et al. 2010). In F9 teratocarcinoma cells PDE6 is ac-
tivated by Wnt5a-Frizzled-2 signaling acting through
transducin, which is also expressed in these cells, and
inhibition of PDE6 with isobutylmethylxanthine, dipy-
ridamole or zaprinast inhibits the formation of primitive
endoderm induced by retinoic acid in these cells, sug-
gesting a role for PDE6 in early embryonic development
(Ahumada, et al. 2002). PDE6 as well as all the other
components of the visual phototransduction pathway
were found to be expressed both in normal melanocytes
and melanoma cells at the mRNA level, but only in mel-
anoma cells at the protein level (Bazhin, et al. 2007). Some
melanoma cell lines expressed Wnt5a and Frizzled-2, and
in these cell lines Wnt5a stimulated PDE6 activity, sug-
gesting that in melanoma, PDE6 may be activated either
by light impinging on rhodopsin, which is expressed in
these cells, or by Wnt5a acting through Frizzled-2 and
transducin (Bazhin, et al. 2010). A functional role for
PDE6 in melanoma cells is still not known. PDE6 catalytic
subunit mRNA and protein were found to be expressed in
both normal and fibrotic human lung tissue, and at com-
parable levels, but expression of the PDE6D regulatory
and PDE6G/H inhibitory subunits were significantly
reduced in fibrotic lung tissue. Overexpression or sup-
pression of PDE6D expression led to changes in cGMP
levels, rate of proliferation, and state of ERK phospho-
rylation, suggesting that alterations in PDE6D expres-
sion and its consequent effects on PDE6 activity may
be a causative factor for idiopathic pulmonary fibrosis
(Nikolova, et al. 2010).
Considerable epidemiologic evidence has been amassed
over the past 25 years demonstrating an association be-
tween increased exposure to LAN and increased rates of
breast cancer (Flynn-Evans, et al. 2009; Kloog, et al. 2010;
Stevens 2009a,b). Specific evidence for this includes in-
creased incidence of breast cancer among women who
work non-day shifts, lower incidence of breast cancer
among totally blind women, an inverse relationship be-
tween breast cancer incidence and sleep duration, and a
correlation between increased incidence of breast cancer
and population LAN levels worldwide. This epidemio-
logical evidence led the International Agency for Research
on Cancer to classify shift work as a probable human car-
cinogen (Straif, et al. 2007). The molecular basis for effects
of LAN on breast cancer are unknown, but inasmuch as
the synthesis and secretion of melatonin from the pineal
gland at night is very sensitive to suppression by LAN
(Vanecek 1998), specifically only blue light in the wave-
length range of 450–480 nm (Sanchez-Barcelo, et al.
2012), the general thinking has been that the reduced
melatonin may be permissive for increased proliferation of
breast epithelial cells and may thus play a role in the in-
creased incidence of breast cancer (Sanchez-Barcelo, et al.
2012). Attention has also focused recently on the pos-
sibility that LAN exposure may affect circadian rythym
through altering the expression of circadian genes and
that this disruption of the circadian rhthym contrib-
utes to breast cancer development (Gery and Koeffler
2010; Savvidis and Koutsilieris 2012; Stevens 2009a, b).
The body’s circadian rythym is normally regulated by the
expression of circadian genes in a master pacemaker in
the suprachiasmatic nucleus of the hypothalamus that
signals to oscillators in peripheral tissues (Savvidis and
Koutsilieris 2012). As shown in this paper (Table 1), as
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Table 1 Expression of phototransduction pathways genes, Wnt genes, and Circadian rhythm genes
Breast cancer cell lines (Average signal) Patients’ breast cancer tissues (1-8) (Average signal)
MCF-7 T47D MB-435 MB-231 1 2 3 4 5 6 7 8
Phototransduction genes
RHO Rhodopsin -45 27 31 87 -43 40 -63 14 -45 -90 13 -1
GRK1 Rhodopsin kinase 4.25 102 70 133.9
GNAT1 variant 1 Rod transducin alpha subunit 0 77 69 133 8 85 -12 54 31 4* 36 46
GNAT1 variant 2 Rod transducin alpha subunit 73 131* 90 124 54* 108 47** 63 60** -7 75* 59
GNAT2 Cone transducin alpha subunit 27 93 83 248** 23 172** -13 26 84** -29 47 40
GNAZ Cone transducin alpha subunit 199** 84 204** 118 139* 132** 131** 80** 255** 8* 250** 301
GNB1 Transducin beta subunit 22340** 14936** 14239** 17968** 20122** 20994** 17661** 15477** 21669** 19486** 20140** 17137**
GNB1L Transducin beta subunit 925** 265** 1160** 1352** 607** 900** 1030** 261** 295** 749** 270** 343**
GNB2 Transducin beta subunit 2968** 675** 1208** 741** 1456** 691** 1171** 773** 3845** 1147** 1066** 1038**
GNG2L Transducin beta subunit 69029** 73280** 43084** 56176** 62765** 50370** 70951** 65617** 74326** 62703** 59073** 25580**
GNB3 Transducin beta subunit 87* 95 136** 118 111* 117* 50** 179** 126** 23** 76** 96
GNB4 Transducin beta subunit 29 2157** 831** 1250** 229** 204** 687** 186** 288** 702** 565** 591
GNB5 variant 1 Transducin beta subunit 37 58 374** 217** 62** 85 58** 61 64** 17** 69 58
GNB5 variant 2 Transducin beta subunit -7 54 31 106 19 73 -29 26 13 -61 7 41
GNGT1 Transducin gamma subunit 60 102 63 113 17 89 -24 63 25 -33 40 31
GNGT2 Transducin gamma subunit -60 64 31 68 7 115 183** 74 15 93** 41 38
SAG Arrestin 1 85 67 107 33 99 -44 107** -1 14** 56 51
RLV1 Recoverin -25 49 59 77 -21 63 7 60 32 -26 19 23
CNGA1 CNG channel alpha subunit 9 64 45 253 16 53 137** 10 139** -50 30 15
CNGA2 CNG channel alpha subunit 3 76 65 97 4 71 -42 41 31 -41 49 33
CNGA3 CNG channel alpha subunit -42 5 41 80 -29 66 -64 70 -30 -83 131** 145**
CNGB1 CNG channel beta subunit 13 23 27 81 6 74 -34 19 -7 -35 15 17
CNGB3 CNG channel beta subunit 14 43 44 95 10 93 -51 53 -18 -57 37 13
Wnt genes
WNT5A Wnt -31 10 293** 113 915** 670** 84** 490** 775** 266** 195** 267**
FZD2 Frizzled-2 864** 1740** 1828** 4896** 1213** 220** 1045** 1576** 1088** 620** 1176** 1186**
Circadian rhythm genes
PER1 Period 1 -25 69 53 80 32 100 -23 64 25 -1 62 102**
PER2 variant1 Period 2 7 56 59 93 -6 72 -31 32 21 -48 41 8
PER2 variant2 Period 2 5176** 2856** 1169** 846** 3847** 2745** 2693** 3234** 4415** 3693** 4735** 4683**
PER3 Period 3 4 64 49 89 6 73 -36 33 43 -12 77* 47
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Table 1 Expression of phototransduction pathways genes, Wnt genes, and Circadian rhythm genes (Continued)
CLOCK Clock 208** 330** 175** 216** 1001* 202* 364** 352** 575** 353** 468** 411*
TIMELESS Timeless 5334** 8868** 3219** 4254** 2094** 1527** 1478** 2427** 1167** 2119** 1836** 1603**
CRY1 Cryptochrome 1 1302** 688* 682** 2693** 402** 1071** 474** 707** 326** 1205** 1052** 1166**
CRY2 Cryptochrome 2 2862** 1014** 494** 334** 1058** 908** 1622** 1611** 2053** 1604** 1171** 1078**
**P<0.01, *P<0.05, Significant values according to statistical variation for each gene probe analyzed on the Illumina array.
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well as by others (Fu, et al. 2011; Hoffman et al. 2010a,b),
circadian genes are expressed directly in breast cancer
epithelial cells as well. Considerable evidence shows that
expression of circadian genes are directly under the regu-
lation of cGMP (Golombek, et al. 2004; Oster, et al. 2003;
Plano, et al. 2012); thus, regulation of PDE6 in breast can-
cer cells by light or by Wnt5a signaling through Frizzled-2
and transducin, all of which we find expressed in breast
cancer cells, could directly regulate the expression of cir-
cadian genes in these cells through alterations in cGMP
levels. Although we find no evidence of rhodopsin in
breast cancer cells to act as a light sensor, we do find high
epression of CRY2 in these cells, and CRY2 can also act as
a light sensor, absorbing light in its associated FAD mol-
ecule, intriguingly also specifically in the blue wavelength
region of 450–480 nm (Hoang, et al. 2008), which may
contribute to the activation of PDE6 in these cells, and the
alteration in cGMP levels, leading to dysregulation of cir-
cadian genes, alterations in circadian rythyms, and the in-
ducement or perpetuation of the growth of breast cancer
cells. It is also noteworthy that increased cGMP levels
have been shown to inhibit proliferation and induce
apoptosis in breast cancer cell lines (Saravani, et al.
2012; Tinsley, et al. 2011) and it is thus possible that
breast cancer cells have evolved to express PDE6 as a
means to protect themselves against cGMP-mediated
apoptosis to ensure their continued growth. While there is
still much to be done to decipher the true function(s) for
the expression of the light-activated PDE6 in breast cancer
cells, this study nevertheless documents the expression of
PDE6 in these cells, thereby uncovering a potential novel
means by which exposure to LAN may result in breast
cancer growth and development.
Conclusions
This paper demonstrates the novel finding of the expres-
sion of PDE6, the light sensitive PDE, previously thought
to be photoreceptor specific, in breast cancer cell lines
and patients’ breast cancer tissues, at both the RNA and
protein levels. This finding is discussed in the context of
epidemiological evidence for exposure to artificial light
at night as a risk factor for breast cancer and in relation
to our further finding of the expression of circadian
rhythm genes in these breast cancer tisssues.
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